search icon
allo-img

Allogene Therapeutics Inc, Common Stock

ALLO

NSQ

$1.145

-$0.03

(-2.54%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$238.42M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
814.49K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.60
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.86 L
$3.78 H
$1.145

About Allogene Therapeutics Inc, Common Stock

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameALLOSectorS&P500
1-Week Return8.26%1.39%1.18%
1-Month Return-23.38%-4.97%6.44%
3-Month Return-39.49%-11.13%-0.73%
6-Month Return-52.42%-10.21%-2.01%
1-Year Return-49.36%-6.5%12.12%
3-Year Return-85.12%0.1%42.84%
5-Year Return-97.55%28.49%93.86%
10-Year Return-95.28%76.62%180.28%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue38.34M38.49M243.00K95.00K22.00K[{"date":"2020-12-31","value":99.63,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":0.63,"profit":true},{"date":"2023-12-31","value":0.25,"profit":true},{"date":"2024-12-31","value":0.06,"profit":true}]
Cost of Revenue11.54M13.06M16.73M242.91M-[{"date":"2020-12-31","value":4.75,"profit":true},{"date":"2021-12-31","value":5.38,"profit":true},{"date":"2022-12-31","value":6.89,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit(11.54M)38.49M243.00K95.00K22.00K[{"date":"2020-12-31","value":-29.99,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":0.63,"profit":true},{"date":"2023-12-31","value":0.25,"profit":true},{"date":"2024-12-31","value":0.06,"profit":true}]
Gross Margin(30.10%)100.00%100.00%100.00%100.00%[{"date":"2020-12-31","value":-30.1,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses258.24M294.28M335.69M327.83M273.22M[{"date":"2020-12-31","value":76.93,"profit":true},{"date":"2021-12-31","value":87.66,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":97.66,"profit":true},{"date":"2024-12-31","value":81.39,"profit":true}]
Operating Income(258.24M)(255.79M)(335.45M)(327.74M)(273.20M)[{"date":"2020-12-31","value":-25824300000,"profit":false},{"date":"2021-12-31","value":-25579200000,"profit":false},{"date":"2022-12-31","value":-33544900000,"profit":false},{"date":"2023-12-31","value":-32773700000,"profit":false},{"date":"2024-12-31","value":-27319900000,"profit":false}]
Total Non-Operating Income/Expense17.19M501.00K7.38M15.27M36.02M[{"date":"2020-12-31","value":47.71,"profit":true},{"date":"2021-12-31","value":1.39,"profit":true},{"date":"2022-12-31","value":20.49,"profit":true},{"date":"2023-12-31","value":42.39,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(250.22M)(257.00M)(332.63M)(327.26M)(257.15M)[{"date":"2020-12-31","value":-25022100000,"profit":false},{"date":"2021-12-31","value":-25700500000,"profit":false},{"date":"2022-12-31","value":-33263200000,"profit":false},{"date":"2023-12-31","value":-32726500000,"profit":false},{"date":"2024-12-31","value":-25714700000,"profit":false}]
Income Taxes(16.75M)(12.17M)(2.82M)(2.82M)443.00K[{"date":"2020-12-31","value":-3781.04,"profit":false},{"date":"2021-12-31","value":-2746.73,"profit":false},{"date":"2022-12-31","value":-635.89,"profit":false},{"date":"2023-12-31","value":-635.89,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income After Taxes(233.47M)(244.84M)(329.81M)(324.45M)(257.59M)[{"date":"2020-12-31","value":-23347100000,"profit":false},{"date":"2021-12-31","value":-24483700000,"profit":false},{"date":"2022-12-31","value":-32981500000,"profit":false},{"date":"2023-12-31","value":-32444800000,"profit":false},{"date":"2024-12-31","value":-25759000000,"profit":false}]
Income From Continuous Operations(250.22M)(257.00M)(332.63M)(332.86M)(257.59M)[{"date":"2020-12-31","value":-25022100000,"profit":false},{"date":"2021-12-31","value":-25700500000,"profit":false},{"date":"2022-12-31","value":-33263200000,"profit":false},{"date":"2023-12-31","value":-33285500000,"profit":false},{"date":"2024-12-31","value":-25759000000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(233.47M)(244.84M)(329.81M)(327.26M)(257.59M)[{"date":"2020-12-31","value":-23347100000,"profit":false},{"date":"2021-12-31","value":-24483700000,"profit":false},{"date":"2022-12-31","value":-32981500000,"profit":false},{"date":"2023-12-31","value":-32726500000,"profit":false},{"date":"2024-12-31","value":-25759000000,"profit":false}]
EPS (Diluted)(2.08)(1.89)(2.32)(2.01)(1.33)[{"date":"2020-12-31","value":-208,"profit":false},{"date":"2021-12-31","value":-189,"profit":false},{"date":"2022-12-31","value":-232,"profit":false},{"date":"2023-12-31","value":-201,"profit":false},{"date":"2024-12-31","value":-133,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ALLO
Cash Ratio 9.33
Current Ratio 9.71

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ALLO
ROA (LTM) -28.92%
ROE (LTM) -59.60%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ALLO
Debt Ratio Lower is generally better. Negative is bad. 0.24
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.76

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ALLO
Trailing PE NM
Forward PE NM
P/S (TTM) 11631.14
P/B 0.65
Price/FCF NM
EV/R 3859.62
EV/Ebitda NM

FAQs

What is Allogene Therapeutics Inc share price today?

Allogene Therapeutics Inc (ALLO) share price today is $1.145

Can Indians buy Allogene Therapeutics Inc shares?

Yes, Indians can buy shares of Allogene Therapeutics Inc (ALLO) on Vested. To buy Allogene Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ALLO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Allogene Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Allogene Therapeutics Inc (ALLO) via the Vested app. You can start investing in Allogene Therapeutics Inc (ALLO) with a minimum investment of $1.

How to invest in Allogene Therapeutics Inc shares from India?

You can invest in shares of Allogene Therapeutics Inc (ALLO) via Vested in three simple steps:

  • Click on Sign Up or Invest in ALLO stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Allogene Therapeutics Inc shares
What is Allogene Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Allogene Therapeutics Inc (ALLO) is $3.78. The 52-week low price of Allogene Therapeutics Inc (ALLO) is $0.86.

What is Allogene Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Allogene Therapeutics Inc (ALLO) is 0.65

What is the Market Cap of Allogene Therapeutics Inc?

The market capitalization of Allogene Therapeutics Inc (ALLO) is $238.42M

What is Allogene Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Allogene Therapeutics Inc is ALLO

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top